Champions Oncology (CSBR) Non-Current Deffered Revenue (2018 - 2019)
Champions Oncology's (CSBR) quarterly Non-Current Deffered Revenue came in at $851000.0 in Q2 2019, up 87.44% year-over-year from $454000.0 in Q2 2018, and up 16.1% on a QoQ basis from $733000.0 in Q1 2019.
Powered by 
Analysis
Champions Oncology (CSBR) Non-Current Deffered Revenue (2018 - 2019) Analysis & Trends
Champions Oncology (CSBR) has 2 years of Non-Current Deffered Revenue data on file, last reported at $851000.0 in Q2 2019.
- On a quarterly basis, Non-Current Deffered Revenue rose 87.44% year-over-year to $851000.0 in Q2 2019; TTM through Apr 2019 was $851000.0, a 87.44% increase from a year earlier, with the FY2019 full-year figure at $851000.0, up 87.44% from the prior year.
- Non-Current Deffered Revenue for Q2 2019 stood at $851000.0, up from $733000.0 in the prior quarter.
- Across five years, Non-Current Deffered Revenue topped out at $851000.0 in Q2 2019 and bottomed at $454000.0 in Q2 2018.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Iqvia Holdings | 44.72 Bn | 42.64 Bn | 1.44 Bn | - |
| 2 | Medpace Holdings | 17.37 Bn | 16.87 Bn | 201.64 Mn | - |
| 3 | Icon | 13.65 Bn | 12.72 Bn | 479.29 Mn | - |
| 4 | Charles River Laboratories International | 13.13 Bn | 12.94 Bn | 452.07 Mn | - |
| 5 | Fortrea Holdings | 1.89 Bn | 1.72 Bn | 139.20 Mn | - |
| 6 | Evotec SE | 574.75 Mn | 148.87 Mn | - | 158.90 Mn |
| 7 | Ginkgo Bioworks Holdings | 439.63 Mn | 355.09 Mn | 18.44 Mn | 76.54 Mn |
| 8 | Champions Oncology | 69.43 Mn | 65.03 Mn | 7.70 Mn | - |
| 9 | MindWalk Holdings | 51.76 Mn | 46.29 Mn | 1.61 Mn | - |
| 10 | VivoSim Labs | 1.37 Mn | 1.37 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Apr 30, 2019 | 851,000.00 |
| Jan 31, 2019 | 733,000.00 |
| Oct 31, 2018 | 669,000.00 |
| Jul 31, 2018 | 605,000.00 |
| Apr 30, 2018 | 454,000.00 |